Please use this identifier to cite or link to this item:
http://hdl.handle.net/123456789/26330
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Muhammad Luqman Nordin | - |
dc.contributor.author | Abdin Shakirin Mohamad Norpi | - |
dc.contributor.author | Ng, Pei Yuen | - |
dc.contributor.author | Khatijah Yusoff | - |
dc.contributor.author | Nadiah Abu | - |
dc.contributor.author | Lim, Kue Peng | - |
dc.contributor.author | Fazren Azmi | - |
dc.contributor.author | (UniKL RCMP) | - |
dc.date.accessioned | 2022-11-23T03:35:21Z | - |
dc.date.available | 2022-11-23T03:35:21Z | - |
dc.date.issued | 2021-10 | - |
dc.identifier.citation | Muhammad Luqman Nordin, Abdin Shakirin Mohamad Norpi, Ng, P. Y., Khatijah Yusoff, Nadiah Abu, Lim, K. P., & Fazren Azmi (2021). HER2/neu-Based Peptide Vaccination-Pulsed with B-Cell Epitope Induced Efficient Prophylactic and Therapeutic Antitumor Activities in TUBO Breast Cancer Mice Model. Cancers, 13(19), 4958. https://doi.org/10.3390/cancers13194958 | en_US |
dc.identifier.issn | 20726694 | - |
dc.identifier.uri | https://www.mdpi.com/2072-6694/13/19/4958 | - |
dc.identifier.uri | http://hdl.handle.net/123456789/26330 | - |
dc.description.abstract | Breast cancer is the most common invasive cancer diagnosed among women. A cancer vaccine has been recognized as a form of immunotherapy with a prominent position in the prevention and treatment of breast cancer. The majority of current breast cancer vaccination strategies aim to stimulate antitumor T-cell responses of the HER2/neu oncogene, which is abnormally expressed in breast cancer cells. However, the role of the B-cell humoral response is often underappreciated in the cancer vaccine design. We have advanced this idea by elucidating the role of B-cells in cancer vaccination by designing a chimeric antigenic peptide possessing both cytotoxic T lymphocytes (GP2) and B-cell (P4) peptide epitopes derived from HER2/neu. The chimeric peptide (GP2–P4) was further conjugated to a carrier protein (KLH), forming a KLH–GP2–P4 conjugate. The immunogenicity of KLH–GP2–P4 was compared with KLH–GP2 (lacking the B-cell epitope) in BALB/c mice. Mice immunized with KLH–GP2–P4 elicited more potent antigen-specific neutralizing antibodies against syngeneic TUBO cells (cancer cell line overexpressing HER2/neu) that was governed by a balanced Th1/Th2 polarization in comparison to KLH–GP2. Subsequently, these immune responses led to greater inhibition of tumor growth and longer survival in TUBO tumor-bearing mice in both prophylactic and therapeutic challenge experiments. Overall, our data demonstrated that the B-cell epitope has a profound effect in orchestrating an efficacious antitumor immunity. Thus, a multi-epitope peptide vaccine encompassing cytotoxic T-lymphocytes, T-helper and B-cell epitopes represents a promising strategy in developing cancer vaccines with a preventive and therapeutic modality for the effective management of breast cancer | en_US |
dc.language.iso | en | en_US |
dc.publisher | MDPI | en_US |
dc.subject | Antitumor | en_US |
dc.subject | B-cell epitope | en_US |
dc.subject | Breast cancer | en_US |
dc.subject | HER2/neu | en_US |
dc.subject | Multi-epitope | en_US |
dc.subject | Peptide vaccines | en_US |
dc.title | HER2/neu-based peptide vaccination-pulsed with B-cell epitope induced efficient prophylactic and therapeutic antitumor activities in TUBO breast cancer mice model | en_US |
dc.type | Article | en_US |
Appears in Collections: | Journal Articles |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
HER2neu-based peptide vaccination-pulsed with B-cell epitope induced efficient prophylactic and therapeutic antitumor activities in TUBO breast cancer mice model.pdf | 3.41 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.